 Repligen Corporation NASDAQ: RGEN has agreed to acquire privately-held Avitide Inc for approximately 150 million in cash and stock. The deal consideration includes 75 million in cash plus 75 million in Repligen common stock in addition to performance-based earnout payments over the next three years. 